pharma · Polycythemia Vera · Ulcerative Colitis Chronic Moderate · PTGX
Protagonist Therapeutics
Protagonist Therapeutics, Inc
Protagonist Therapeutics is a pharma organization headquartered in Newark, USA. It trades on NYSE under ticker PTGX. Primary therapeutic focus areas include Polycythemia Vera, Ulcerative Colitis Chronic Moderate, Celiac
7707 Gateway Blvd, Suite 140, Newark, California 94560, US HQ
2006 Founded
153 Employees
Public company Type
PTGX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 7707 Gateway Blvd, Suite 140, Newark, California 94560, US
- Founded
- 2006
- Employees
- 153
- Programs
- 13
- Drugs
- 5
- Patents
- 33
PTG-100
Phase 2 · small molecule · Ulcerative Colitis
PTG-100 for Ulcerative Colitis is a Phase 2 program (small_molecule) at Protagonist Therapeutics, Inc with 1 ClinicalTrials.gov record(s).
Internal code PTG-100-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Protagonist Therapeutics, Inc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Ulcerative Colitis
- Status
- terminated
- Trials
- 1